Research location
Lynchburg
Virginia, United States
Advertisement
Research activity in Lynchburg
Virginia, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 178 trials and 178 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Lynchburg
178 linked trials · page 2 of 4Benefits of Microcor in Ambulatory Decompensated Heart FailureNCT04096040 · 2019-11-01 · 1 site observation
COMPLETED
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)NCT03988634 · 2019-06-29 · 1 site observation
COMPLETED
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)NCT03971474 · 2019-05-28 · 1 site observation
COMPLETED
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)NCT03845296 · 2019-04-16 · 1 site observation
COMPLETED
Long-term Safety and Efficacy Extension Trial of Bimatoprost SRNCT03891446 · 2019-03-27 · 1 site observation
COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782 · 2019-02-28 · 1 site observation
COMPLETED
Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast CancerNCT03633331 · 2018-08-15 · 1 site observation
COMPLETED
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450 · 2018-07-13 · 1 site observation
COMPLETED
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 SignalingNCT03412643 · 2018-05-14 · 1 site observation
UNKNOWN
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeNCT03473223 · 2018-03-21 · 1 site observation
COMPLETED
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)NCT03373045 · 2018-02-27 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 2018-02-16 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation
TERMINATED
Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)NCT03446573 · 2018-01-18 · 1 site observation
COMPLETED
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboNCT03281954 · 2017-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung CancerNCT03373760 · 2017-11-30 · 1 site observation
COMPLETED
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsNCT03299049 · 2017-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Understanding and Predicting Breast Cancer Events After TreatmentNCT02791581 · 2017-07-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15 · 1 site observation
COMPLETED
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerNCT03377556 · 2017-03-03 · 1 site observation
COMPLETED
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerNCT02954874 · 2017-01-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MINCT02924727 · 2016-12-09 · 1 site observation
COMPLETED
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsNCT02951052 · 2016-10-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsNCT02938520 · 2016-10-27 · 1 site observation
ACTIVE_NOT_RECRUITING
Breast Cancer WEight Loss Study (BWEL Study)NCT02750826 · 2016-09-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)NCT02595944 · 2016-07-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Reveal LINQ™ Heart FailureNCT02758301 · 2016-06-08 · 1 site observation
COMPLETED
Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.NCT02554890 · 2016-04-29 · 1 site observation
COMPLETED
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02785952 · 2015-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant ChemotherapyNCT02445391 · 2015-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular HypertensionNCT02507687 · 2015-08-27 · 1 site observation
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast CancerNCT02488967 · 2015-07-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)NCT02451137 · 2015-06-16 · 1 site observation
COMPLETED
Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine RegimenNCT02478632 · 2015-06-12 · 1 site observation
COMPLETED
Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)NCT02429791 · 2015-04-14 · 1 site observation
COMPLETED
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)NCT02201992 · 2015-03-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation
COMPLETED
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular HypertensionNCT02247804 · 2014-12-15 · 1 site observation
COMPLETED
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01 · 1 site observation
COMPLETED
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02965378 · 2014-10-01 · 1 site observation
COMPLETED
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26 · 1 site observation
ACTIVE_NOT_RECRUITING
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02785939 · 2014-09-01 · 1 site observation
COMPLETED
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersNCT02766335 · 2014-07-31 · 1 site observation
COMPLETED
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08 · 1 site observation
COMPLETED
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT02164513 · 2014-06-30 · 1 site observation
COMPLETED
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02926638 · 2014-06-16 · 1 site observation
TERMINATED
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerNCT02032823 · 2014-04-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.